EZI Activators
EZI activators, or Enhancer of Zeste Inhibitor activators, are a class of chemical compounds that specifically interact with a family of proteins known as Polycomb-group (PcG) proteins. PcG proteins are involved in the regulation of gene expression through the modification of chromatin structure, which is the complex of DNA and protein found in the nucleus of eukaryotic cells. One of the key components of this protein family is the Enhancer of Zeste homolog 2 (EZH2), which acts as a methyltransferase, transferring methyl groups to histone proteins-the core components around which DNA is wound. This methylation is a critical process in the epigenetic regulation of genes, playing an essential role in the control of gene activation and repression. EZI activators are designed to modulate the activity of EZH2, thereby influencing the methylation status of histones and ultimately affecting the expression pattern of genes.
The molecular design of EZI activators is rooted in the understanding of the enzymatic mechanism of EZH2. By binding to the catalytic site or allosteric sites of EZH2, these activators can modulate the activity of the enzyme. The structure-activity relationship (SAR) of these molecules is an active area of research, focusing on optimizing the interactions between the EZI activators and EZH2 proteins to achieve desired modulation effects. These compounds are often characterized by their ability to influence the tri-methylation state of histone H3 on lysine 27 (H3K27me3), which is a hallmark of EZH2 enzymatic activity. Understanding the precise mechanism by which EZI activators exert their effect on EZH2 involves detailed studies of molecular biology, biochemistry, and structural biology to elucidate the interaction between these small molecules and their target protein at the atomic level.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which can then phosphorylate target proteins, leading to the activation of EZI through phosphorylation-dependent mechanisms. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective phosphodiesterase inhibitor, preventing the breakdown of cAMP and thereby maintaining high intracellular levels of this second messenger. This can support the activation of EZI by sustaining PKA activity, which may phosphorylate EZI. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which is involved in various signal transduction pathways. PKC activation can lead to downstream effects that enhance the activation state of EZI through phosphorylation of related substrates. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit several protein kinases, which could reduce negative regulatory phosphorylation events, indirectly enhancing the activity of EZI by relieving inhibitory control mechanisms. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can modulate downstream AKT signaling. Inhibition of AKT can lead to activation of certain processes or proteins that may be suppressed by AKT, potentially leading to the indirect activation of EZI. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, and by blocking this kinase, it can influence the MAPK/ERK pathway. This may lead to altered signaling dynamics that indirectly enhance the activity of EZI by impacting related signaling networks. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate is a bioactive lipid that activates sphingosine-1-phosphate receptors, triggering intracellular signaling cascades. This can lead to the activation of signaling pathways that indirectly increase the functional activity of EZI. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, activating calcium-dependent signaling pathways. This can lead to the activation of proteins and processes that are modulated by calcium signaling, potentially enhancing the functional activity of EZI. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor, which may lead to the selective activation of certain pathways by inhibiting kinases that normally suppress them, possibly resulting in the indirect activation of EZI. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can alleviate competitive signaling and enhance pathways that lead to the activation of EZI by decreasing the activity of competing tyrosine kinases. | ||||||